These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 37110810)

  • 41. Role of orexin in the pathophysiology of depression: potential for pharmacological intervention.
    Nollet M; Leman S
    CNS Drugs; 2013 Jun; 27(6):411-22. PubMed ID: 23657787
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Orexin/hypocretin receptor modulation of anxiolytic and antidepressive responses during social stress and decision-making: Potential for therapy.
    Summers CH; Yaeger JDW; Staton CD; Arendt DH; Summers TR
    Brain Res; 2020 Mar; 1731():146085. PubMed ID: 30590027
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Multiple-dose clinical pharmacology of the selective orexin-1 receptor antagonist ACT-539313.
    Kaufmann P; Ort M; Golor G; Kornberger R; Dingemanse J
    Prog Neuropsychopharmacol Biol Psychiatry; 2021 Jun; 108():110166. PubMed ID: 33159976
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Induction of narcolepsy-like symptoms by orexin receptor antagonists in mice.
    Kaushik MK; Aritake K; Cherasse Y; Imanishi A; Kanbayashi T; Urade Y; Yanagisawa M
    Sleep; 2021 Aug; 44(8):. PubMed ID: 33609365
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An Update on Dual Orexin Receptor Antagonists and Their Potential Role in Insomnia Therapeutics.
    Janto K; Prichard JR; Pusalavidyasagar S
    J Clin Sleep Med; 2018 Aug; 14(8):1399-1408. PubMed ID: 30092886
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Investigation of New Orexin 2 Receptor Modulators Using
    Janockova J; Dolezal R; Nepovimova E; Kobrlova T; Benkova M; Kuca K; Konecny J; Mezeiova E; Melikova M; Hepnarova V; Ring A; Soukup O; Korabecny J
    Molecules; 2018 Nov; 23(11):. PubMed ID: 30423961
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Relationship between orexin A and childhood maltreatment in female patients with depression and anxiety.
    Ozsoy S; Olguner Eker O; Abdulrezzak U; Esel E
    Soc Neurosci; 2017 Jun; 12(3):330-336. PubMed ID: 27043067
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Involvement of orexin-A in the regulation of neuronal activity and emotional behaviors in central amygdala in rats.
    Pan YP; Liu C; Liu MF; Wang Y; Bian K; Xue Y; Chen L
    Neuropeptides; 2020 Apr; 80():102019. PubMed ID: 31980205
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Orexin Receptor Antagonists: Historical Perspectives and Future Opportunities.
    Andrews SP; Aves SJ; Christopher JA; Nonoo R
    Curr Top Med Chem; 2016; 16(29):3438-3469. PubMed ID: 26416477
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Daridorexant for the treatment of insomnia disorder: findings and implications.
    Dos Santos JBR; da Silva MRR
    Eur J Clin Pharmacol; 2022 Nov; 78(11):1749-1761. PubMed ID: 36098753
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Orexin Receptor Antagonists as Adjunct Drugs for the Treatment of Depression: A Mini Meta-Analysis.
    Uğurlu M
    Noro Psikiyatr Ars; 2024; 61(1):77-84. PubMed ID: 38496221
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Orexin Receptor Antagonism Improves Sleep and Reduces Seizures in Kcna1-null Mice.
    Roundtree HM; Simeone TA; Johnson C; Matthews SA; Samson KK; Simeone KA
    Sleep; 2016 Feb; 39(2):357-68. PubMed ID: 26446112
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Non-selective orexin-receptor antagonist attenuates stress-re-stress-induced core PTSD-like symptoms in rats: Behavioural and neurochemical analyses.
    Prajapati SK; Krishnamurthy S
    Behav Brain Res; 2021 Feb; 399():113015. PubMed ID: 33212086
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Orexin/hypocretin and major psychiatric disorders.
    Lin CC; Huang TL
    Adv Clin Chem; 2022; 109():185-212. PubMed ID: 35953127
    [TBL] [Abstract][Full Text] [Related]  

  • 55. SB 334867, a selective orexin receptor type 1 antagonist, elevates seizure threshold in mice.
    Socała K; Szuster-Ciesielska A; Wlaź P
    Life Sci; 2016 Apr; 150():81-8. PubMed ID: 26916826
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evidence-based insomnia treatment strategy using novel orexin antagonists: A review.
    Kishi T; Nishida M; Koebis M; Taninaga T; Muramoto K; Kubota N; Moline M; Sakuma K; Okuya M; Nomura I; Iwata N
    Neuropsychopharmacol Rep; 2021 Dec; 41(4):450-458. PubMed ID: 34553844
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The Orexinergic (Hypocretin) System and Nociception: An Update to Supraspinal Mechanisms.
    Roohbakhsh A; Alavi MS; Azhdari-Zarmehri H
    Curr Med Chem; 2018; 25(32):3917-3929. PubMed ID: 28552056
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Causes and Consequences of Chronic Sleep Deficiency and the Role of Orexin.
    Mullington JM; Cunningham TJ; Haack M; Yang H
    Front Neurol Neurosci; 2021; 45():128-138. PubMed ID: 34052807
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The role of trigeminal nucleus caudalis orexin 1 receptor in orofacial pain-induced anxiety in rat.
    Bahaaddini M; Khatamsaz S; Esmaeili-Mahani S; Abbasnejad M; Raoof M
    Neuroreport; 2016 Oct; 27(15):1107-13. PubMed ID: 27563736
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Preclinical and clinical results of dual orexin receptor antagonist, suvorexant (BELSOMRA(®)), a novel therapeutic agent for insomnia].
    Tanaka Y; Aoki I; Ishine T; Renger JJ; Winrow CJ; Hisada S
    Nihon Yakurigaku Zasshi; 2016 Jul; 148(1):46-56. PubMed ID: 27430679
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.